UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

The New England journal of medicine, 2018-11, Vol.379 (18), p.1711-1721

2018

Volltextzugriff (PDF)

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Frontiers in oncology, 2020-01, Vol.9, p.1380-1380

2020

Volltextzugriff (PDF)

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3230-3237

2007

Volltextzugriff (PDF)

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3133-3140

2009

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Heat shock proteins: a potential anticancer target

Current drug targets, 2011-12, Vol.12 (14), p.2001-2008

2011

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1885-1893

2005

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.570-576

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.563-569

2008

Volltextzugriff (PDF)

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.946-953

2019

Volltextzugriff (PDF)

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Cancer chemotherapy and pharmacology, 2015-03, Vol.75 (3), p.495-503

2015

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Journal of clinical oncology, 2006-02, Vol.24 (4), p.552-562

2006

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Cancer epidemiology, biomarkers & prevention, 2003-11, Vol.12 (11), p.1213-1221

2003

Volltextzugriff (PDF)

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Clinical cancer research, 2009-01, Vol.15 (1), p.346-354

2009

Volltextzugriff (PDF)

Maximum tolerated dose: clinical endpoint for a bygone era?

Targeted oncology, 2009-04, Vol.4 (2), p.143-147

Takimoto, Chris H.

2009

Volltextzugriff (PDF)

Design, conduct, and interpretation of organ impairment studies in oncology patients

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3509-3510

2006

Volltextzugriff (PDF)

Improving attribution of adverse events in oncology clinical trials

Cancer treatment reviews, 2019-06, Vol.76, p.33-40

2019

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

European journal of cancer (1990), 2009-09, Vol.45, p.436-438

Takimoto, Chris H

2009

Volltextzugriff (PDF)

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

Investigational new drugs, 2019-02, Vol.37 (1), p.76-86

2019

Volltextzugriff (PDF)

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

The oncologist (Dayton, Ohio), 2008-10, Vol.13 (10), p.1043-1045

Takimoto, Chris H.

2008

Volltextzugriff (PDF)

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Biochemistry (Easton), 1993-05, Vol.32 (18), p.4756-4760

1993

Volltextzugriff (PDF)

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial

Molecular cancer therapeutics, 2011-01, Vol.10 (1), p.209-217

2011

Volltextzugriff (PDF)

Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor

Medical oncology (Northwood, London, England), 2003-01, Vol.20 (4), p.403-408

2003

Volltextzugriff (PDF)

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

Seminars in oncology, 2003-08, Vol.30 (4 Suppl 15), p.14-19

2003

Volltextzugriff (PDF)

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Clinical cancer research, 2010-10, Vol.16 (19_Supplement), p.PL6-1-PL6-1

Takimoto, Chris H.

2010

Volltextzugriff (PDF)

1 – 25 von 83

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(83)

Erscheinungsjahr

n.n

Thema

Humans
(43)
Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Oncology
(31)
Female
(23)
Male
(22)
Adult
(20)
Neoplasms - Drug Therapy
(20)
Middle Aged
(19)
Aged
(18)
Antineoplastic Agents - Pharmacokinetics
(12)
Biological And Medical Sciences
(12)
Antineoplastic Agents - Pharmacology
(10)
Antineoplastic Agents - Administration & Dosage
(9)
Antineoplastic Agents - Adverse Effects
(9)
Antineoplastic Agents - Therapeutic Use
(9)
Medical Sciences
(9)
Tumors
(9)
Aged, 80 And Over
(8)
Pharmacology & Pharmacy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Heat shock proteins: a potential anticancer target

Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid Tumors

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function

Phase I Pharmacokinetic and Pharmacodynamic Analysis of Unconjugated Soy Isoflavones Administered to Individuals with Cancer

Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients

Maximum tolerated dose: clinical endpoint for a bygone era?

Design, conduct, and interpretation of organ impairment studies in oncology patients

Improving attribution of adverse events in oncology clinical trials

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules

Commentary: Tumor Growth, Patient Survival, and the Search for the Optimal Phase II Efficacy Endpoint

Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro

Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial

Doege-Potter syndrome: hypoglycemia associated with malignant solitary fibrous tumor

Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the national cancer institute organ dysfunction working group

Blazing the pharmacologic audit trail: Pharmacodynamic biomarkers in early drug development

Aktive Filter

Suchergebnisse filtern